ClinicalTrials.gg
Status unknownNCT04706286Updated Jan 12, 2021

Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393

A Phase 1 interventional study of CKD-501, D759, D150 and CKD-393 0.5/100/1000 mg in T2DM (Type 2 Diabetes Mellitus), sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
17th of 23
26 · median 41
Started
2021
the only one that year
Phase 1
14 of 23
none open now
Registered
20th of 23
by date
Lead sponsor
20 of 23
Chong Kun Dang Pharmaceutical

Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 17th largest by planned enrollment, is the only one that started in 2021, is one of 14 in phase 1, and was the 20th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

About lobeglitazone

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

A Clinical Trial to evaluate the Pharmacokinetics and safety of CKD-393 0.5/100/1000 mg under fed condition

Read the detailed description

A Phase 1 Clinical Trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of CKD-393 0.5/100/1000 mg under fed condition.

03

Conditions studied

  • T2DM (Type 2 Diabetes Mellitus)
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult who is 19 \~ 55 years at the time of screening
  2. Body weight more than 55 kg for male and more than 50kg for female
  3. more than 18.5 kg/m2 or less than 27.0 kg/m2
  4. Females must be menopause or surgical infertility
  5. Males who have consented to the use of appropriate pregnancy methods up to 28 days after the last product and not to provide sperm
  6. Subjects who voluntarily decided to participate and based upon understanding on the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a history of hepatic, renal, nervous, immune, respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic disease or psychosis disorder
  2. Subjects who have genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  3. Subjects with poor oral intake, susceptible to dehydration or clinically significant dehydration
  4. Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of the drug
  5. Subjects who have a history of clinically significant to drugs or additives
  6. Subjects who have severe infectious disease and severe trauma before and after operation
  7. Subjects who have undergone i.v. testing of radioactive iodine contrast material within 48 hours before the first IP administration
  8. Subjects who are deemed unsuitable as subjects in the screening test performed within 28 days before the administration of product

    • , ALT> UNL(Upper Normal Limit)x1.25
    • (Estimated Glomerular Filtration Rate) \<60 mL/min/1.73m2 using the MDRD (Modification of Diet in Renal Disease) equation
    • Positive immunologic serological tests ( test, test, (HIV) test, syphilis test)
    • After resting for more than 5 minutes, systolic blood pressure> 150 mmHg or \< 90 mmHg, diastolic blood pressure> 100 mmHg or \<50 mmHg
  9. Subjects who have had a history of drug abuse within one year of screening or have tested positive on urine drug screening test
  10. Subjects who judged to able to affect in the study or in the subject's safety by the investigator for the following reasons

    • Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first administration of the investigational drug.
    • Over-the-counter (OTC) drugs, including health foods and vitamin preparations, within 7 days of the first dose of the investigational product
    • Inducing or inhibiting drugs of drug-metabolism enzyme, within 30 days of the first dose of the investigational product
  11. Subjects who have consistently excessively smoked or consumed caffeine or alcohol (caffeine:> 5 cups / day, alcohol:> 210 g / week, cigarettes:> 10 cigarettes / day) or cannot stop smoking, consuming caffeine and alcohol during hospitalization
  12. Subjects who take grapefruit-containing food within 7 days before IP administration, or cannot forbid taking grapefruit-containing food for period of clinical trials.
  13. Subjects who have received the investigational product by participating in other clinical trials (including bioequivalence studies) within 180 days before the first dose of the investigational product (For biological agents, this may be based on a longer period of time, considering the half-life)
  14. Subjects who donated whole blood within 60 days before the first dose of the investigational product or donated component blood donation within 30 days
  15. Subjects who received a blood transfusion within 30 days before the first dose of the investigational product
  16. Pregnant or lactating women
  17. Subjects who were deemed to be inappropriate to participate in the study by the investigator judgment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Group 1

    1. Period 1: Treatment A 2. Period 2: Treatment B

    Drug: CKD-501, D759, D150 · Drug: CKD-393 0.5/100/1000 mg

  • Experimental
    Group 2

    1. Period 1: Treatment B 2. Period 2: Treatment A

    Drug: CKD-501, D759, D150 · Drug: CKD-393 0.5/100/1000 mg

Interventions

  • CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition

    Also known as: Treatment A

  • DrugCKD-393 0.5/100/1000 mg

    CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition

    Also known as: Treatment B

06

What researchers measure

Primary outcomes

  1. AUCt(Area Under Curve last) of CKD-393

    Area under the plasma concentration time curve of CKD-393, from time zero up to the last measurable concentration.

    Time frame: From predose, upto 48 hours post-dose

  2. Cmax of CKD-393

    The maximum concentration observed of CKD-393 over blood sampling time.

    Time frame: From predose, upto 48 hours post-dose

07

Study locations

1 site
  • Severance Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2021; primary completion for Mar 2021, 1 month later.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2021
First posted
Jan 12, 2021
StartEst.
Feb 18, 2021
Primary completionEst.
Mar 29, 2021
CompletionEst.
Apr 5, 2021
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04706286
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
Feb 18, 2021 (estimated)
Primary completion
Mar 29, 2021 (estimated)
Completion
Apr 5, 2021 (estimated)
Last update
Jan 12, 2021

Study contacts

Choon Ok Kim, M.D., Ph.D.
Contact
DELIVERY98@yuhs.ac
+82-2-2228-0455
Choon Ok Kim, M.D., Ph.D.
principal investigator · Severance hospital of the Yonsei University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lobeglitazone

Start the discussion